A 91-year-old female presented with widespread skin sloughing and bullae clinically mimicking toxic epidermal necrolysis (TEN). The patient was on multiple antibiotics, including vancomycin and piperacillin/tazobactam. Histopathology and direct immunofluorescence were consistent with a diagnosis of linear IgA bullous disease (LABD). In a PubMed review of the literature from 1975 to the present, there have been 15 cases of LABD presenting as TEN clinically and with characteristic linear IgA deposits on direct immunofluorescence studies. Vancomycin and phenytoin were the most commonly implicated medications. Twelve patients saw a resolution or healing of skin lesions after discontinuation of the implicated medication. There were, however, 5 patients who died of complications related to their comorbidities. It is important to include LABD in the differential diagnosis when evaluating patients who clinically present with TEN.

Keywords:
Bullous disease, Linear IgA bullous dermatosis, Toxic epidermal necrolysis
1.
Fortuna G, Marinkovich PM: Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012;30:38-50.
2.
Dellavalle RP, Burch JM, Tayal S, Golitz LE, Fitzpatrick JE, Walsh P: Vancomycin associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. J Am Acad Dermatol 2003;48:S56-S57.
3.
Leonard JN, Griffith CEM, Powles AV, et al: Experience with a gluten free diet in the treatment of linear IgA disease. Acta Derm Venereol 1987;67:145-148.
4.
Egan CA, Meadows KP, Zone J: Ulcerative colitis and immunobullous disease cured by colectomy. Arch Dermatol 1999;135:214-215.
5.
Barberis C, Doutre MS, Bioulac-Sage P, et al: Dermatose bulleuse à IgA linéaire associée à une maladie de Crohn. Gastroenterol Clin Biol 1988;12:76-77.
6.
McEvoy MT, Connolly SM: Linear IgA bullous dermatosis: association with malignancy. J Am Acad Dermatol 1990;22:59-63.
7.
Sekula SA, Tschen JA, Bean SF, Wolf JE Jr: Linear IgA bullous disease in a patient with transitional cell carcinoma of the bladder. Cutis 1986;38:354-356, 362.
8.
Lacour JP, Vitetta A, Ortonne JP: Linear IgA dermatosis and thyroid carcinoma. J Am Acad Dermatol 1992;26:257-259.
9.
Barrow-Wade L, Jordan RE, Arnett FC Jr: Linear IgA bullous dermatosis associated with dermatomyositis (letter). Arch Dermatol 1992;128:413-414.
10.
Blickenstaff RD, Perry HO, Peters MS: Linear IgA deposition associated with cutaneous varicella-zoster infection: a case report. J Cutan Pathol 1988;15:49-52.
11.
Buchvald J, Filo V, Horvathova J: IgA-linear dermatosis imitating Lyell syndrome. Bratisl Lek Listy 1987;88:211-217.
12.
Paul D, Wolkenstein P, Prost C, Caux F, Rostoker G, Heller M, Wechsler J, Revuz J, Roujeau JC: Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol 1997;136:406-411.
13.
Wetterwald E, Le Cleach L, Wechsler J, Roujeau JC, Revuz J, Bagot M: Bullous drug eruption masquerading as toxic epidermal necrolysis. Eur Rencontres Hop 1999;45:15-18.
14.
Schneck B, Termeer C, Mockenhaupt M, Augustin M, Schöpf E: Linear IgA dermatosis in an adult with clinical signs of Stevens-Johnson syndrome. Hautarzt 1999;50:288-291.
15.
Mofid MZ, Costarangos C, Bernstein B, Wong L, Munster A, Nousari HC: Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:246-247.
16.
Hughes AP, Callen JP: Drug-induced linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Dermatology 2001;202:138-139.
17.
Tran D, Kossard S, Shumack S: Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis. Australas J Dermatol 2003;44:284-286.
18.
Waldman MA, Black DR, Callen JP: Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004;29:633-636.
19.
Coelho S, Tellechea O, Reis JP, Mariano A, Figueiredo A: Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Int J Dermatol 2006;137:995-996.
20.
Cummings JE, Snyder RR, Kelly EB, Raimer SS: Drug-induced linear immunoglobulin A bullous dermatosis mimicking Stevens-Johnson syndrome: a case report. Cutis 2007;79:203-207.
21.
Khan I, Hughes R, Curran R, Marren P: Drug-associated linear IgA disease mimicking toxic epidermal necrolysis. Clin Exp Dermatol 2009;34:715-717.
22.
Trufant JW, Christensen SR, McNiff JM, Choi JN: Erythroderma and spontaneous blistering in a 49-year-old man. Arch Dermatol 2010;146:1419-1424.
23.
Schroeder D, Saada D, Rafaa M, Ingen-Housz-Oro S, Valeyrie-Alannore L, Siggal ML: Verapamil-induced linear IgA disease mimicking toxic-epidermal necrolysis. Ann Dermatol Venereol 2011;138:302-306.
24.
Jheng-Wei L, Yi-Chin S, Wen-Hung C: Vancomycin-induced linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. Indian J Dermatol Venereol Leprol 2011;77:537.
25.
Zone JJ, Taylor TB, Kadunce DP, Meyer LJ: Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990;85:812-820.
26.
Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ: LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996;106:734-738.
27.
Collier P, Wojnarowska F, Allen J, Kirtschig G: Molecular overlap of the IgA target antigens in the subepidermal blistering diseases. Dermatology 1994;189(suppl 1):105-107.
28.
Kanitakis J, Mauduit G, Cozzani E, Badinand P, Faure M, Claudy A: Linear IgA bullous dermatosis of childhood with autoantibodies to a 230 kDa epidermal antigen. Pediatr Dermatol 1994;11:139-144.
29.
Hirako Y, Usukura J, Uematsu J, Hashimoto T, Kitajima Y, Owaribe K: Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 1998;273:9711-9717.
30.
Zone JJ, Taylor TB, Meyer LJ, Petersen MJ: The 97 kDa linear IgA bullous disease antigen is identical to a portion of the extracellular domain of the 180 kDa bullous pemphigoid antigen, BPAg2. J Invest Dermatol 1998;110:207-210.
31.
Allen J, Phan TT, Hughes MA, Cherry GW, Wojnarowska F: The cellular origins of the linear IgA disease target antigens: an indirect immunofluorescence study using cultured human keratinocytes and fibroblasts. Br J Dermatol 2003;148:945-953.
32.
Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP: A critical reappraisal of the current data on drug induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol 2012;66:988-994.
33.
Lissia M, Mulas P, Bulla A, Rubino C: Toxic epidermal necrolysis (Lyell's disease). Burns 2010;36:152-163.
34.
Klein PA, Callen JP: Drug-induced linear IgA bullous dermatosis after vancomycin discontinuance in a patient with renal insufficiency. J Am Acad Dermatol 2000;42:316-323.
35.
Walsh S, Kerchner K, Sangueza OP: Localized palmar vancomycin-induced linear IgA bullous dermatosis occurring at supratherapeutic levels. Arch Dermatol 2009;145:603-604.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.